Citius Oncology Inc (CTOR)

$0.70 -0.04 (-5.41%)
Market Cap 68.81M
Revenue (ttm) 0.00
Net Income (ttm) -24.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.34
Volume 86,500
Avg Vol 93,136
Day's Range N/A - N/A
Shares Out 92.98M
Stochastic %K 16%
Beta 3.48
Analysts Strong Sell
Price Target $4.00

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 967 6677
Address:
11 Commerce Drive, First Floor, Cranford, United States
xanadu74
xanadu74 Aug. 17 at 2:59 AM
$CTOR Thoughts on valuation? Assuming they keep the same (disappointingly low) rate of revenue, they will have $9.4M revenue this year. Added 29 additional sales resources, so can we expect the revenue to double next year to say $20M ? At 10x this year's revenue, they should be valued at $94M and 10x forward looking revenue, they should be at $180M valuation. At 20x (which is not uncommon based on ChatGPT) - the potential doubles. Short term down - longer term 4-5x return. Any thoughts?
0 · Reply
Jojackthewonderskunk
Jojackthewonderskunk Aug. 14 at 10:40 PM
$CTOR hosed again.
0 · Reply
Reesifer
Reesifer Aug. 14 at 10:28 PM
$CTOR added .72
0 · Reply
TwongStocks
TwongStocks Aug. 14 at 8:38 PM
$CTOR $CTXR $1.5M in revenue last quarter. LOWER than the $1.7M reported for Jan-March.
3 · Reply
donein12
donein12 Aug. 14 at 3:04 PM
$CTOR 5 hours for the financials to be released, and absolutely no one is interested in CTOR based on the trading. Kinda says everything. Of course the standard excuse is investors are just waiting.However to me investors do not expect much.
1 · Reply
TwongStocks
TwongStocks Aug. 14 at 2:04 PM
$CTOR $CTXR Previous quarter ended on June 30. 10-Q filings for non-accelerated filers are due today, 45 days after the end of the quarter. Last week, CTOR issued a PR to highlight that institutions ordering LYMPHIR increased by 78%. But it appears they are going to wait until AH on a Friday, the last day to file the 10-Q, before they disclose the actual revenue numbers. Classic Leonard 😂
0 · Reply
kunnskap
kunnskap Aug. 12 at 5:21 PM
$CTOR
1 · Reply
TwongStocks
TwongStocks Aug. 12 at 12:08 PM
$CTOR Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri https://www.prnewswire.com/news-releases/citius-oncology-expands-board-with-appointment-of-independent-director-jonathan-peri-302849254.html
0 · Reply
kunnskap
kunnskap Aug. 11 at 1:49 PM
$CTOR Buy rating reaffirmed.$$4 price target and commercial sales booming.....tick tock
0 · Reply
kunnskap
kunnskap Aug. 10 at 6:49 PM
$CTOR $4.X Price target maintained. Trading at under 20% of the value. Time to load up?
0 · Reply
Latest News on CTOR
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026, 4:30 PM EDT - 4 days ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

CTXR

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026, 4:30 PM EDT - 4 days ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

CTXR

Citius Oncology Quarterly report: Q3 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Citius Oncology Quarterly report: Q3 2026

Citius Oncology Earnings release: Q3 2026

Aug 14, 2026, 7:00 AM EDT - 5 days ago

Citius Oncology Earnings release: Q3 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CTXR

Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3

2026-08-05T13:47:34.000Z - 14 days ago

Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3

CTXR

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Aug 5, 2026, 9:17 AM EDT - 14 days ago

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

CTXR

Citius Oncology provides update on commercial launch of Lymphir

2026-07-21T13:25:39.000Z - 4 weeks ago

Citius Oncology provides update on commercial launch of Lymphir

CTXR

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Jul 21, 2026, 9:17 AM EDT - 4 weeks ago

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

CTXR

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

2026-06-01T12:16:52.000Z - 2 months ago

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

CTXR

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

CTXR

Citius Oncology registers to sell 32.93M shares of common stock for holders

2026-05-29T20:41:31.000Z - 2 months ago

Citius Oncology registers to sell 32.93M shares of common stock for holders

Citius Oncology Registration statement: Registration filing

May 29, 2026, 8:00 AM EDT - 2 months ago

Citius Oncology Registration statement: Registration filing

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

May 26, 2026, 8:00 AM EDT - 3 months ago

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

CTXR

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 4:30 PM EDT - 3 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTXR

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 4:30 PM EDT - 3 months ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTXR

Citius Oncology Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Citius Oncology Quarterly report: Q2 2026

Citius Oncology Earnings release: Q2 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Citius Oncology Earnings release: Q2 2026

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

May 5, 2026, 8:00 PM EDT - 3 months ago

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology announces initial shipment of LYMPHIR to Europe

2026-04-29T14:53:58.000Z - 4 months ago

Citius Oncology announces initial shipment of LYMPHIR to Europe

CTXR

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

CTXR

Citius Oncology provides commercial update on lymphir launch

2026-03-31T13:40:30.000Z - 5 months ago

Citius Oncology provides commercial update on lymphir launch

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Mar 31, 2026, 9:11 AM EDT - 5 months ago

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

CTXR

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

CTXR

Citius Oncology’s Lymphir shows positive results in gynecologic cancers

2026-03-10T12:58:01.000Z - 5 months ago

Citius Oncology’s Lymphir shows positive results in gynecologic cancers

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Mar 10, 2026, 8:47 AM EDT - 5 months ago

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

CTXR

Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR

2026-03-04T14:21:26.000Z - 6 months ago

Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

Mar 4, 2026, 9:15 AM EST - 6 months ago

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

CTXR

Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

2026-02-13T13:16:23.000Z - 6 months ago

Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

CTXR

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

2026-02-13T13:10:44.000Z - 6 months ago

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

CTXR

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Feb 13, 2026, 8:00 AM EST - 6 months ago

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTXR

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Feb 13, 2026, 8:00 AM EST - 6 months ago

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTXR

Citius Oncology Quarterly report: Q1 2026

Feb 13, 2026, 7:00 AM EST - 6 months ago

Citius Oncology Quarterly report: Q1 2026

Citius Oncology Earnings release: Q1 2026

Feb 13, 2026, 7:00 AM EST - 6 months ago

Citius Oncology Earnings release: Q1 2026

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Feb 11, 2026, 8:00 AM EST - 6 months ago

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

CTXR

Citius Oncology Registration statement: Registration filing

Jan 5, 2026, 7:00 AM EST - 8 months ago

Citius Oncology Registration statement: Registration filing

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

2025-12-23T21:40:21.000Z - 8 months ago

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025, 4:30 PM EST - 8 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025, 4:30 PM EST - 8 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTXR

Citius Oncology Annual report: Q4 2025

Dec 23, 2025, 7:00 AM EST - 8 months ago

Citius Oncology Annual report: Q4 2025

Citius Oncology Earnings release: Q4 2025

Dec 23, 2025, 7:00 AM EST - 8 months ago

Citius Oncology Earnings release: Q4 2025

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 10, 2025, 4:30 PM EST - 8 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

2025-12-09T13:35:42.000Z - 9 months ago

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

CTXR

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025, 8:30 AM EST - 9 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTXR

Citius Oncology expands Lymphir distribution to Turkey and Middle East

2025-12-04T13:40:29.000Z - 9 months ago

Citius Oncology expands Lymphir distribution to Turkey and Middle East

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Dec 4, 2025, 8:37 AM EST - 9 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTXR

Citius Oncology announces U.S. commercial launch of LYMPHIR

2025-12-01T17:10:12.000Z - 9 months ago

Citius Oncology announces U.S. commercial launch of LYMPHIR

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Dec 1, 2025, 12:00 PM EST - 9 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTXR

Citius Oncology Slides: Corporate presentation

Dec 1, 2025, 7:00 AM EST - 9 months ago

Citius Oncology Slides: Corporate presentation

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2025, 8:00 AM EST - 9 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTXR

Citius Oncology to advance launch of Lymphir with Verix AI integration

2025-11-21T13:45:33.000Z - 9 months ago

Citius Oncology to advance launch of Lymphir with Verix AI integration

CTXR

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Nov 21, 2025, 8:37 AM EST - 9 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTXR

Citius Oncology announces distribution agreement with McKesson

2025-10-20T12:40:10.000Z - 10 months ago

Citius Oncology announces distribution agreement with McKesson

CTXR MCK

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Oct 20, 2025, 8:37 AM EDT - 10 months ago

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Oct 17, 2025, 5:00 PM EDT - 10 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTXR

Citius Oncology signs exclusive commercialization agreement with EVERSANA

2025-10-16T12:50:19.000Z - 10 months ago

Citius Oncology signs exclusive commercialization agreement with EVERSANA

CTXR

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oct 16, 2025, 8:47 AM EDT - 10 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTXR

Citius Oncology signs distribution agreement for Lymphir in Southern Europe

2025-10-07T12:56:18.000Z - 11 months ago

Citius Oncology signs distribution agreement for Lymphir in Southern Europe

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Oct 7, 2025, 8:47 AM EDT - 11 months ago

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

Citius Oncology Proxy statement: Proxy filing

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Citius Oncology Proxy statement: Proxy filing

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 10, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTXR

Citius Oncology Registration statement: Registration filing

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Citius Oncology Registration statement: Registration filing

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Aug 22, 2025, 8:47 AM EDT - 1 year ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTXR

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Earnings release: Q3 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Earnings release: Q3 2025

Citius Oncology Quarterly report: Q3 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Quarterly report: Q3 2025

Citius Oncology Announces Closing of $9.0 Million Public Offering

Jul 17, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTXR

Citius Oncology Announces Pricing of $9.0 Million Public Offering

Jul 16, 2025, 9:15 AM EDT - 1 year ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTXR

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Jul 15, 2025, 8:32 AM EDT - 1 year ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTXR

Citius Oncology Registration statement: Registration filing

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Citius Oncology Registration statement: Registration filing

Citius Oncology Registration statement: Registration filing

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Citius Oncology Registration statement: Registration filing

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Jun 17, 2025, 8:08 AM EDT - 1 year ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTXR

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Quarterly report: Q2 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Quarterly report: Q2 2025

Citius Oncology Earnings release: Q2 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Citius Oncology Earnings release: Q2 2025

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 8:37 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTXR

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTXR

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Oncology Quarterly report: Q1 2025

Feb 13, 2025, 7:00 AM EST - 1 year ago

Citius Oncology Quarterly report: Q1 2025

Citius Oncology Earnings release: Q1 2025

Feb 13, 2025, 7:00 AM EST - 1 year ago

Citius Oncology Earnings release: Q1 2025

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTXR

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTXR

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTXR

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

xanadu74
xanadu74 Aug. 17 at 2:59 AM
$CTOR Thoughts on valuation? Assuming they keep the same (disappointingly low) rate of revenue, they will have $9.4M revenue this year. Added 29 additional sales resources, so can we expect the revenue to double next year to say $20M ? At 10x this year's revenue, they should be valued at $94M and 10x forward looking revenue, they should be at $180M valuation. At 20x (which is not uncommon based on ChatGPT) - the potential doubles. Short term down - longer term 4-5x return. Any thoughts?
0 · Reply
Jojackthewonderskunk
Jojackthewonderskunk Aug. 14 at 10:40 PM
$CTOR hosed again.
0 · Reply
Reesifer
Reesifer Aug. 14 at 10:28 PM
$CTOR added .72
0 · Reply
TwongStocks
TwongStocks Aug. 14 at 8:38 PM
$CTOR $CTXR $1.5M in revenue last quarter. LOWER than the $1.7M reported for Jan-March.
3 · Reply
donein12
donein12 Aug. 14 at 3:04 PM
$CTOR 5 hours for the financials to be released, and absolutely no one is interested in CTOR based on the trading. Kinda says everything. Of course the standard excuse is investors are just waiting.However to me investors do not expect much.
1 · Reply
TwongStocks
TwongStocks Aug. 14 at 2:04 PM
$CTOR $CTXR Previous quarter ended on June 30. 10-Q filings for non-accelerated filers are due today, 45 days after the end of the quarter. Last week, CTOR issued a PR to highlight that institutions ordering LYMPHIR increased by 78%. But it appears they are going to wait until AH on a Friday, the last day to file the 10-Q, before they disclose the actual revenue numbers. Classic Leonard 😂
0 · Reply
kunnskap
kunnskap Aug. 12 at 5:21 PM
$CTOR
1 · Reply
TwongStocks
TwongStocks Aug. 12 at 12:08 PM
$CTOR Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri https://www.prnewswire.com/news-releases/citius-oncology-expands-board-with-appointment-of-independent-director-jonathan-peri-302849254.html
0 · Reply
kunnskap
kunnskap Aug. 11 at 1:49 PM
$CTOR Buy rating reaffirmed.$$4 price target and commercial sales booming.....tick tock
0 · Reply
kunnskap
kunnskap Aug. 10 at 6:49 PM
$CTOR $4.X Price target maintained. Trading at under 20% of the value. Time to load up?
0 · Reply
Bren10OD
Bren10OD Aug. 6 at 12:50 AM
$CTOR this has to clear a dollar by eow, right? Business is good…
0 · Reply
kunnskap
kunnskap Aug. 5 at 5:38 PM
$CTOR The proof is in the pudding.
0 · Reply
PennySearch
PennySearch Aug. 5 at 3:33 PM
📈 Top Penny Stock Movers by Relative Volume $FLZH — 18.01x RVOL Move: +16% Volume: 4.1M (227.9K average) Market Cap: $1.8M Day Range: 1.11 – 1.44 52-Week Range: 1.11 – 37.00 $KLTR — 8.71x RVOL Move: +38% Volume: 4.2M (477.1K average) Market Cap: $289.5M Day Range: 1.43 – 1.96 52-Week Range: 1.05 – 2.01 $CTOR — 8.52x RVOL Move: +14% Volume: 696.0K (81.7K average) Market Cap: $70.7M Day Range: 0.63 – 0.89 52-Week Range: 0.49 – 2.25 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.
0 · Reply
kunnskap
kunnskap Aug. 5 at 3:02 PM
$CTOR Up 26% today and still way undervalued. Come join the fun!!
0 · Reply
focafoca99
focafoca99 Aug. 5 at 2:12 PM
$CTOR highlights a growing base of institutional accounts ordering LYMPHIR.
0 · Reply
kunnskap
kunnskap Aug. 5 at 2:11 PM
$CTOR Time to shine
0 · Reply
JackCampbell
JackCampbell Aug. 5 at 1:42 PM
$CTOR Citius Oncology announced a strong 78% quarter-over-quarter (QoQ!!!!) increase in medical accounts ordering LYMPHIR, expanding its footprint across 42 top US cancer centers and regional clinics. This commercial momentum is driven by rising repeat vial orders from healthcare providers alongside near 100% insurer coverage ahead of their full sales force rollout. https://finance.yahoo.com/healthcare/articles/citius-oncology-reports-strong-commercial-131700198.html
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 5 at 1:17 PM
$CTOR Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
1 · Reply
donein12
donein12 Aug. 3 at 1:42 PM
$CTOR Even though the financials will not be released untill late next week, the results are are known with management in the company. So what ever happens now till the release may inducate how the results will be, since there are always leaks that occur. However with Mazur's history in reality you cannot expect any great news.
1 · Reply
ekpemofolo
ekpemofolo Jul. 28 at 6:25 PM
$CTOR Earnings coming up in a couple of weeks. My idea from few months ago haven't changed. Initial stocking and subsequent disappointing quarter are behind us. Without a sales force in place during the quarter, I will rein in my usual optimism and assume no growth in sales at all. Even then, my calculation gives $4.2 m revenue for this quarter. Dumb penny-market will take it as a huge Q-to-Q increase, and there will be fireworks here. That is my view and it is not investment advice.
1 · Reply
Stockinvestor73
Stockinvestor73 Jul. 25 at 2:15 AM
$ADAPY i found the perfexr reverse merger target........ It's $CTOR
0 · Reply
TwongStocks
TwongStocks Jul. 21 at 1:28 PM
$CTOR Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Nationwide-Deployment-of-LYMPHIRs-Broadened-Commercial-Organization-and-Expanding-Market-Adoption/default.aspx "Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August " 8 months after commercial launch, they'll finally have a full commercial & medical affairs team.
1 · Reply